Juno Investors Reach $24M Deal In Stock-Drop Class Action
A certified class of investors in Juno Therapeutics told a Washington federal judge on Thursday that it has reached a $24 million settlement to resolve claims that the biopharmaceutical company's failure...To view the full article, register now.
Already a subscriber? Click here to view full article